본문 바로가기
KERD
논문KCI 등재

Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective

Gwyneth Soon|Aileen Wee
대한간학회 (The korean Association for the Study of the Liver)|2021.01|Clinical and Molecular Hepatology|제27권 제1호|pp. 44-57|DOI 10.3350/cmh.2020.0181

2

조회

0

다운로드

9

인용

0

참고문헌

키워드

BiopsyFibrosisNonalcoholic fatty liver disease

초록

Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) is a major cause of liver fibrosis and cirrhosis. Accurate assessment of liver fibrosis is important for predicting disease outcomes and assessing therapeutic response in clinical practice and clinical trials. Although noninvasive tests such as transient elastography and magnetic resonance elastography are preferred where possible, histological assessment of liver fibrosis via semiquantitative scoring systems remains the current gold standard. Collagen proportionate area provides more granularity by measuring the percentage of fibrosis on a continuous scale, but is limited by the absence of architectural input. Although not yet used in routine clinical practice, advances in second harmonic generation/two-photon excitation fluorescence (SHG/TPEF) microscopy imaging show great promise in characterising architectural features of fibrosis at the individual collagen fiber level. Quantification and calculation of different detailed variables of collagen fibers can be used to establish algorithm-based quantitative fibrosis scores (e.g., qFibrosis, q-FPs), which have been validated against fibrosis stage in NAFLD. Artificial intelligence is being explored to further refine and develop quantitative fibrosis scoring methods. SHG-microscopy shows promise as the new gold standard for the quantitative measurement of liver fibrosis. This has reaffirmed the pivotal role of the liver biopsy in fibrosis assessment in NAFLD, at least for the near-future. The ability of SHG-derived algorithms to intuitively detect subtle nuances in liver fibrosis changes over a continuous scale should be employed to redress the efficacy endpoint for fibrosis in NASH clinical trials; this approach may improve the outcomes of the trials evaluating therapeutic response to antifibrotic drugs.

Abstract

Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) is a major cause of liver fibrosis and cirrhosis. Accurate assessment of liver fibrosis is important for predicting disease outcomes and assessing therapeutic response in clinical practice and clinical trials. Although noninvasive tests such as transient elastography and magnetic resonance elastography are preferred where possible, histological assessment of liver fibrosis via semiquantitative scoring systems remains the current gold standard. Collagen proportionate area provides more granularity by measuring the percentage of fibrosis on a continuous scale, but is limited by the absence of architectural input. Although not yet used in routine clinical practice, advances in second harmonic generation/two-photon excitation fluorescence (SHG/TPEF) microscopy imaging show great promise in characterising architectural features of fibrosis at the individual collagen fiber level. Quantification and calculation of different detailed variables of collagen fibers can be used to establish algorithm-based quantitative fibrosis scores (e.g., qFibrosis, q-FPs), which have been validated against fibrosis stage in NAFLD. Artificial intelligence is being explored to further refine and develop quantitative fibrosis scoring methods. SHG-microscopy shows promise as the new gold standard for the quantitative measurement of liver fibrosis. This has reaffirmed the pivotal role of the liver biopsy in fibrosis assessment in NAFLD, at least for the near-future. The ability of SHG-derived algorithms to intuitively detect subtle nuances in liver fibrosis changes over a continuous scale should be employed to redress the efficacy endpoint for fibrosis in NASH clinical trials; this approach may improve the outcomes of the trials evaluating therapeutic response to antifibrotic drugs.

참고문헌 (97)

  1. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
  2. Younossi Z, "Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates", Clin Gastroenterol Hepatol, 17, pp.748~755.e3 (2019)
  3. Li J, "Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 4, pp.389~398 (2019)
  4. Hagström H, "Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD", J Hepatol, 67, pp.1265~1273 (2017)
  5. Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 149, pp.389~397.e10 (2015)
  6. Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis", Hepatology, 65, pp.1557~1565 (2017)
  7. Ekstedt M, "Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up", Hepatology, 61, pp.1547~1554 (2015)
  8. Castera L, "Non-invasive tests for liver fibrosis in NAFLD: creating pathways between primary healthcare and liver clinics", Liver Int, 40(Suppl 1), pp.77~81 (2020)
  9. Tapper EB, "Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD", Nat Rev Gastroenterol Hepatol, 15, pp.274~282 (2018)
  10. European Association for the Study of the Liver (EASL), "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
  11. Shiha G, "Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update", Hepatol Int, 11, pp.1~30 (2017)
  12. Castera L, "Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease", Gastroenterology, 156, pp.1264~1281.e4 (2019)
  13. Sanyal AJ, "Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration joint workshop", Hepatology, 61, pp.1392~1405 (2015)
  14. Liou I, "Natural history of nonalcoholic steatohepatitis", J Clin Gastroenterol, 40(Suppl 1), pp.S11~S16 (2006)
  15. Fassio E, "Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies", Hepatology, 40, pp.820~826 (2004)
  16. Chávez-Tapia NC, "Role of nonalcoholic fatty liver disease in hepatocellular carcinoma", Ann Hepatol, 8(Suppl 1), pp.S34~S39 (2009)
  17. Bedossa P, "Diagnosis of non-alcoholic fatty liver disease", non-alcoholic steatohepatitis: why liver biopsy is essential, 2018, pp.38(Suppl 1), 64~66
  18. Wanless IR, "Quantitative SHG-microscopy: unraveling the nanoarchitecture of the cirrhotic liver", Clin Res Hepatol Gastroenterol, 44, pp.1~3 (2020)
  19. Ratziu V, "Why do so many NASH trials fail?", Gastroenterology, pp.046~ (2020)[DOI]
  20. Brunt EM, "Steatohepatitis Clinical Research Network. Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials", Hepatology, 70, pp.522~531 (2019)
  21. Friedman SL, "Liver fibrosis -- from bench to bedside", J Hepatol, 38(Suppl 1), pp.S38~S53 (2003)
  22. Schwabe RF, "Mechanisms of fibrosis development in nonalcoholic steatohepatitis", Gastroenterology, 158, pp.1913~1928 (2020)
  23. Kleiner DE, "Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children", Clin Liver Dis, 20, pp.293~312 (2016)
  24. Younossi ZM, "Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis", Hepatology, 68, pp.349~360 (2018)
  25. Xinrong Zhang, "Application of transient elastography in nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 26(2), pp.128~141 (2020), 대한간학회[DOI]
  26. Park CC, "Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease", astroenterology, 152, pp.598~607.e2 (2017)
  27. Kaswala DH, "Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016", Dig Dis Sci, 61, pp.1356~1364 (2016)
  28. Loomba R, "Role of imaging-based biomarkers in NAFLD: recent advances in clinical application and future research directions", J Hepatol, 68, pp.296~304 (2018)
  29. Banerjee R, "Multiparametric magnetic resonance for the noninvasive diagnosis of liver disease", J Hepatol, 60, pp.69~77 (2014)
  30. McDonald N, "Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study", Sci Rep, 8, pp.9189~ (2018)
  31. Angulo P, "The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD", Hepatology, 45, pp.846~854 (2007)
  32. Guha IN, "Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers", Hepatology, 47, pp.455~460 (2008)
  33. Shah AG, "Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 7, pp.1104~1112 (2009)
  34. Xiao G, "Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a metaanalysis", Hepatology, 66, pp.1486~1501 (2017)
  35. Ampuero J, "Development and validation of hepamet fibrosis scoring system-a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis", Clin Gastroenterol Hepatol, 18, pp.216~225.e5 (2020)
  36. Lin B, "Novel serum biomarkers for noninvasive diagnosis and screening of nonalcoholic fatty liver disease-related hepatic fibrosis", OMICS, 23, pp.181~189 (2019)
  37. Loomba R, "Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease", Cell Metab, 25, pp.1054~1062.e5 (2017)
  38. Caussy C, "A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease", Nat Commun, 10, pp.1406~ (2019)
  39. Younossi ZM, "An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease", BMC Med, 16, pp.170~ (2018)
  40. Pirola CJ, "Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity", World J Gastroenterol, 24, pp.1601~1615 (2018)
  41. Hardy T, "Imaging-based assessment of steatosis, inflammation and fibrosis in NAFLD", rr Hepatology Rep, 16, pp.298~307 (2017)
  42. Karsdal MA, "Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar", Aliment Pharmacol Ther, 40, pp.233~249 (2014)
  43. Salarian M, "Early detection and staging of chronic liver diseases with a protein MRI contrast agent", Nat Commun, 10, pp.4777~ (2019)
  44. Fuchs BC, "Molecular MRI of collagen to diagnose and stage liver fibrosis", J Hepatol, 59, pp.992~998 (2013)
  45. Li S, "Liver fibrosis conventional and molecular imaging diagnosis update", J Liver, 8, pp.236~ (2019)
  46. Ratziu V, "Sampling variability of liver biopsy in nonalcoholic fatty liver disease", Gastroenterology, 128, pp.1898~1906 (2005)
  47. Ooi GJ, "Evaluation of the histological variability of core and wedge biopsies in nonalcoholic fatty liver disease in bariatric surgical patients", Surg Endosc (2020)[DOI]
  48. Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
  49. Vuppalanchi R, "Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 7, pp.481~486 (2009)
  50. Bedossa P, "Sampling variability of liver fibrosis in chronic hepatitis C", Hepatology, 38, pp.1449~1457 (2003)
  51. Goldstein NS, "Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens", Am J Clin Pathol, 123, pp.382~387 (2005)
  52. Colloredo G, "Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease", J Hepatol, 39, pp.239~244 (2003)
  53. Brunt EM, "Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions", Am J Gastroenterol, 94, pp.2467~2474 (1999)
  54. Sanyal AJ, "Endpoints and clinical trial design for nonalcoholic steatohepatitis", Hepatology, 54, pp.344~353 (2011)
  55. Brunt EM, "Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings", Hepatology, 53, pp.810~820 (2011)
  56. Bedossa P, "Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease", Hepatology, 60, pp.565~575 (2014)
  57. Bedossa P, "Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients", Hepatology, 56, pp.1751~1759 (2012)
  58. Nascimbeni F, "Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease", J Hepatol, 72, pp.828~838 (2020)
  59. Poynard T, "Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis", Clin Gastroenterol Hepatol, 10, pp.657~663.e7 (2012)
  60. Brunt EM, "Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation", Hepatol Commun, 1, pp.370~378 (2017)
  61. Pai RK, "Standardising the interpretation of liver biopsies in nonalcoholic fatty liver disease clinical trials", Aliment Pharmacol Ther, 50, pp.1100~1111 (2019)
  62. Singh S, "Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies", Clin Gastroenterol Hepatol, 13, pp.643~654 (2015)
  63. Sun Y, "New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment", Hepatology, 65, pp.1438~1450 (2017)
  64. Theise ND, "Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification", Mod Pathol, 31, pp.1191~1200 (2018)
  65. Bedossa P, "Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease", Gastroenterology, 150, pp.1811~1822.e4 (2016)
  66. Standish RA, "An appraisal of the histopathological assessment of liver fibrosis", Gut, 55, pp.569~578 (2006)
  67. Calvaruso V, "Computer-assisted image analysis of liver collagen:relationship to Ishak scoring and hepatic venous pressure gradient", Hepatology, 49, pp.1236~1244 (2009)
  68. Tsochatzis E, "Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis", J Hepatol, 60, pp.948~954 (2014)
  69. Buzzetti E, "Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease", Aliment Pharmacol Ther, 49, pp.1214~1222 (2019)
  70. Forlano R, "High-throughput, machine learning-based quantification of steatosis, inflammation, ballooning, and fibrosis in biopsies from patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 18, pp.2081~2090.e9 (2020)
  71. Hall AR, "Sample size requirement for digital image analysis of collagen proportionate area in cirrhotic livers", Histopathology, 62, pp.421~430 (2013)
  72. Masugi Y, "Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease", Hepatol Commun, 2, pp.58~68 (2017)
  73. Gailhouste L, "Fibrillar collagen scoring by second harmonic microscopy: a new tool in the assessment of liver fibrosis", J Hepatol, 52, pp.398~406 (2010)
  74. Guilbert T, "A robust collagen scoring method for human liver fibrosis by second harmonic microscopy", Opt Express, 18, pp.25794~25807 (2010)
  75. Sun W, "Nonlinear optical microscopy: use of second harmonic generation and twophoton microscopy for automated quantitative liver fibrosis studies", J Biomed Opt, 13, pp.064010~ (2008)
  76. Chang PE, "Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease", PLoS One, 13, pp.e0199166~ (2018)
  77. Liu F, "Second harmonic generation reveals subtle fibrosis differences in adult and pediatric nonalcoholic fatty liver disease", Am J Clin Pathol, 148, pp.502~512 (2017)
  78. Pirhonen J, "Continuous grading of early fibrosis in nafld using label-free imaging: a proof-of-concept study", PLoS One, 11, pp.e0147804~ (2016)
  79. Wang Y, "Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis", Hepatology, 65, pp.1891~1903 (2017)
  80. Xu S, "qFibrosis:a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients", J Hepatol, 61, pp.260~269 (2014)
  81. Wang Y, "Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy", Gut, 69, pp.1116~1126 (2020)
  82. Liu F, "qFIBS:an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis", Hepatology, 71, pp.1953~1966 (2020)
  83. Yu Y, "Deep learning enables automated scoring of liver fibrosis stages", Sci Rep, 8, pp.16016~ (2018)
  84. Gawrieh S, "Automated quantification and architectural pattern detection of hepatic fibrosis in NAFLD", Ann Diagn Pathol, 47, pp.151518~ (2020)
  85. Decaris ML, "Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood", Hepatology, 65, pp.78~88 (2017)
  86. Kanta J, "Elastin in the liver", Front Physiol, 7, pp.491~ (2016)
  87. Nakayama H, "Presence of perivenular elastic fibers in nonalcoholic steatohepatitis fibrosis stage III", Histol Histopathol, 23, pp.407~409 (2008)
  88. Mann DA, "Transcriptional regulation of hepatic stellate cell activation", Gut, 50, pp.891~896 (2002)
  89. Washington K, "Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver", Hum Pathol, 31, pp.822~828 (2000)
  90. Feldstein AE, "Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 3, pp.384~389 (2005)
  91. Trautwein C, "Hepatic fibrosis:concept to treatment", J Hepatol, 62(1 Suppl), pp.S15~S24 (2015)
  92. Hammoutene A, "Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease", J Hepatol, 70, pp.1278~1291 (2019)
  93. Baiocchini A, "Liver sinusoidal endothelial cells (LSECs) modifications in patients with chronic hepatitis C", Sci Rep, 9, pp.8760~ (2019)
  94. Wattacheril J, "Differential intrahepatic phospholipid zonation in simple steatosis and nonalcoholic steatohepatitis", PLoS One, 8, pp.e57165~ (2013)
  95. Hall Z, "Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease", Hepatology, 65, pp.1165~1180 (2017)
  96. Urasaki Y, "Quantitative assessment of liver steatosis and affected pathways with molecular imaging and proteomic profiling", Sci Rep, 8, pp.3606~ (2018)
  97. Jeong-Ju Yoo, "Recent research trends and updates on nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 25(1), pp.1~11 (2019), 대한간학회

이 간행물의 다른 논문 (23건)

Current understanding of primary biliary cholangitisAtsushi Tanakapp. 1-21The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver diseaseChristopher D. Byrne, Erica Jennisonpp. 22-43Recent updates on the management of autoimmune hepatitisAtsumasa Komoripp. 58-69The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the futureAtsunori Tsuchiya, Yusuke Watanabe, Shuji Teraipp. 70-80Drug-drug interactions with direct-acting antivirals — less is moreGrace Lai-Hung Wongpp. 81-82
원문 보기